- The report contains detailed information about Abbott Laboratories that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Abbott Laboratories. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Abbott Laboratories financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Abbott Laboratories competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Abbott Laboratories business.
About Abbott LaboratoriesAs of FY 2016, Abbott Laboratories saw its revenue rising up 2.20% to USD 20,853.0 million compared to the previous year. Its gross profit rose by 1.34% to USD 11,842.0 million against FY 2015 with USD 11,685.0 million. Company’s operating income also increase by 6.87% in FY 2016, but Abbott’s gross profit declined significantly by 68.35% to USD 1,400.0 million.
As of FY 2016, Abbott Laboratories saw its revenue rising up 2.20% to USD 20,853.0 million compared to the previous year. Its gross profit rose by 1.34% to USD 11,842.0 million against FY 2015 with USD 11,685.0 million. Company’s operating income also increase by 6.87% in FY 2016, but Abbott’s gross profit declined significantly by 68.35% to USD 1,400.0 million.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. The companys segments include Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products
This segment offers a line of adult and pediatric pharmaceuticals manufactured, marketed, and sold worldwide and are generally sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies.
The principal products included in the Pharmaceutical Products segment are Humira, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease; TriCor, Trilipix, Simcor, and Niaspan, for the treatment of dyslipidemia; Kaletra, Aluvia, and Norvir, protease inhibitors for the treatment of HIV infection; Synthroid, for the treatment of hypothyroidism; Lupron, also marketed as Lucrin, and Lupron Depot, used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids; Depakote, an agent for the treatment of epilepsy and bipolar disorder and the prevention of migraines; the anesthesia products sevoflurane (sold in the United States under the trademark Ultane and outside of the United States primarily under the trademark Sevorane and in a few other markets as Ultane), isoflurane, and enflurane; the anti-infective clarithromycin (sold under the trademarks Biaxin, Klacid, and Klaricid), and various forms of the antibiotic erythromycin, sold primarily as PCE or polymercoated erythromycin, Erythrocin, and E.E.S.; Zemplar, for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease and Stage 5 treatment; and Ogastro (lansoprazole), a proton pump inhibitor that is marketed outside of the United States and used principally for the short-term treatment of gastroesophageal reflux disease, duodenal ulcers, gastric ulcers, and erosive esophagitis.
This segment offers a line of diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, alternate-care testing sites, and plasma protein therapeutic companies. The segment's products are generally marketed and sold directly from Abbott-owned distribution centers and public warehouses and third-party distributors. Outside the United States, sales are made either directly to customers or through distributors. The company owns Ibis Biosciences, Inc.
The principal products included in the Diagnostic Products segment are immunoassay systems, including ARCHITECT, AxSYM, IMx, Commander, Abbott PRISM, TDx, and TDxFlx; chemistry systems, such as ARCHITECT c4000, c8000, and c16000; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases such as hepatitis and HIV; the m2000, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples and detects and measures infectious agents, including HIV, HBV, HCV, HPV, and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit and the UroVysion bladder cancer recurrence kit; a full line of hematology systems and reagents known as the Cell-Dyn series; and the i-STAT point-of-care diagnostic systems and tests for blood analysis.
In addition, under a distribution agreement with Celera Group, the Diagnostic Products segment distributes certain Celera molecular diagnostic products, including the Viroseq HIV genotyping system and products used for the detection of mutations in the CFTR gene, which causes cystic fibrosis.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. ABBOTT LABORATORIES COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. ABBOTT LABORATORIES BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. ABBOTT LABORATORIES SWOT ANALYSIS
4. ABBOTT LABORATORIES FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. ABBOTT LABORATORIES COMPETITORS AND INDUSTRY ANALYSIS
5.1. Abbott Laboratories Direct Competitors
5.2. Comparison of Abbott Laboratories and Direct Competitors Financial Ratios
5.3. Comparison of Abbott Laboratories and Direct Competitors Stock Charts
5.4. Abbott Laboratories Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Abbott Laboratories Industry Position Analysis
6. ABBOTT LABORATORIES NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. ABBOTT LABORATORIES EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. ABBOTT LABORATORIES ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. ABBOTT LABORATORIES IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. ABBOTT LABORATORIES PORTER FIVE FORCES ANALYSIS2
12. ABBOTT LABORATORIES VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Abbott Laboratories Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Abbott Laboratories Key Executives
Key Executives Biographies1
Key Executives Compensations1
Abbott Laboratories Major Shareholders
Abbott Laboratories History
Abbott Laboratories Products
Revenues by Segment
Revenues by Region
Abbott Laboratories Offices and Representations
Abbott Laboratories SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Abbott Laboratories Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Abbott Laboratories Capital Market Snapshot
Abbott Laboratories Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Abbott Laboratories Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Abbott Laboratories Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Abbott Laboratories Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Abbott Laboratories 1-year Stock Charts
Abbott Laboratories 5-year Stock Charts
Abbott Laboratories vs. Main Indexes 1-year Stock Chart
Abbott Laboratories vs. Direct Competitors 1-year Stock Charts
Abbott Laboratories Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?